The purpose of the HCM Registry is to find ways of predicting the risk of developing complications associated with HCM, so that the most appropriate advice and treatment can be given to patients.
This study will carry out a careful and thorough assessment of people with HCM using new sophisticated tests to identify markers that are associated with these complications.
The information we gather from this research will help doctors in the future identify people with HCM who are at higher risks of developing complications as a result of the disease and give the most appropriate treatment.
Who Is Carrying Out This Research?
This research is funded by the National Institutes of Health (nih.gov), grant number HL117006, by a grant from Cytokinetics, and by the Thomas Fund at the University of Virginia.
The University of Virginia, USA, and the University of Oxford, UK, are organising this research. This study involves 40 research sites in the U.S, Canada and Europe and will enrol 2750 people with HCM over 2 years, followed up for up to 5 years. See Study Locations.
This study has been listed in clinicaltrials.gov (identifier NCT01915615), a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.